NoGeneST™ Anti-MUC1 Aptamer, aMUC1 aptamer-1 sodium

Name: NoGeneST™ Anti-MUC1 Aptamer, aMUC1 aptamer-1 sodium
SKU: NRYF-0625-HZ16
Rating: 5 (1 reviews)

[CAT#: NRYF-0625-HZ16]

A DNA aptamer that specifically targets the tumor-associated antigen MUC1, designed for the selective delivery of agents to cancer cells.

Target:: MUC1

Type:: DNA

Datasheet MSDS Request COA

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Inquiry

Product Overview

Description

This is an 86-base single-stranded DNA (ssDNA) aptamer engineered to bind with high specificity to the extracellular domain of Mucin 1 (MUC1). Because MUC1 is aberrantly overexpressed and displays altered glycosylation on the surface of many epithelial cancer cells, this aptamer serves as a high-precision ligand for targeted therapies. It is designed to deliver conjugated payloads, such as cytotoxic drugs or imaging agents, directly to tumor sites while minimizing exposure to healthy tissues.

Type

DNA

Properties

Size

1 mg; 5 mg; 10 mg

Appearance

Supplied as light yellow oil.

Purity

>90%

Shipping

Room temperature

Storage

Powder Form: Stable for 3 years when stored at -20°C.
In Solvent: Stable for 6 months when aliquoted and stored at -80°C

Research Use Only

For Research Use Only

Target Details

Target

MUC1

Full Name

Mucin 1

Alternative Names

CD227; Polymorphic epithelial mucin (PEM); Epithelial membrane antigen (EMA); Peanut-reactive urinary mucin (PUM)

Gene ID

4582

Uniprot ID

P15941

Target Overview

Mucin 1 (MUC1) is a large, heavily glycosylated transmembrane protein found on the surface of most secretory epithelial tissues. In normal, healthy cells, it is expressed exclusively on the apical surface, where it contributes to lubrication and pathogen protection. In contrast, during malignant transformation (i.e., in carcinomas), MUC1 expression is frequently lost from the apical surface and becomes overexpressed across the entire cell membrane. This cancer-associated MUC1 also exhibits abnormal, truncated glycosylation, which exposes new protein epitopes. This combination of overexpression and altered structure makes MUC1 a prominent tumor-associated antigen and an ideal target for developing cancer-specific diagnostics and targeted therapies.

Publications